Let me remind everyone: Pre-clinical drug data sel

Let me remind everyone: Pre-clinical drug data seldom increases the stock price. And if it does, it is short lived because it has little to sustain it since clinical trials may still be months or years away, and revenues many years beyond that.

What is unique about AMBS is.....LymPro. LymPro is only 4 months away from revenues. We will be getting important data on Lympro in days. The concreteness of Lympro is what's important because the market needs a foundation that is firm for it to speculate on. The reality of LymPro's near term revenue is our saving grace.

But my opinion is that once the market feels confident about LymPro's reality, enough for it to start buying into AMBS....the looming potential of MANF will take on a different dimension. Since Lympro was sufficient reason for the market to bet on AMBS, MANF's future potential makes that bet even more appealing!

And there you have it...that is how irrational exuberance commences in a stock like AMBS. Our strength is the one two punch of LymPro's near term revenues, and MANF's long term monster potential.

The word "patience" sucks, but it applies right now. We're going to be alright.